Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)
This review provides the main results of clinical trials and the literature on the experience of using pegvisomant, the first drug from the class of growth hormone receptor antagonists. The mechanism of action of the drug, its effectiveness with respect to disease control and its effect on complicat...
Main Authors: | Larisa K. Dzeranova, Alexandra A. Povaliaeva, Anastasia A. Romanova, Elena G. Przhiyalkovskaya, Ekaterina A. Pigarova, Natalia S. Fedorova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2019-12-01
|
Series: | Ожирение и метаболизм |
Subjects: | |
Online Access: | https://www.omet-endojournals.ru/jour/article/view/12207 |
Similar Items
-
Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma
by: Ahmed O. Kaseb, et al.
Published: (2022-10-01) -
Brazilian multicenter study on pegvisomant treatment in acromegaly
by: Cesar L. Boguszewski, et al. -
Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
by: Leandro Kasuki, et al.
Published: (2016-10-01) -
Pegvisomant in acromegaly: a multicenter real-life study in Argentina
by: Natalia Ximena Garcia Basavilbaso, et al. -
Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
by: Lingyun Ma, et al.
Published: (2020-08-01)